Vise Technologies, Inc. Genmab A/S Transaction History
Vise Technologies, Inc.
- $2.32 Billion
- Q2 2025
A detailed history of Vise Technologies, Inc. transactions in Genmab A/S stock. As of the latest transaction made, Vise Technologies, Inc. holds 14,458 shares of GMAB stock, worth $415,089. This represents 0.01% of its overall portfolio holdings.
Number of Shares
14,458
Previous 12,892
12.15%
Holding current value
$415,089
Previous $269,000
10.78%
% of portfolio
0.01%
Previous 0.02%
Shares
3 transactions
Others Institutions Holding GMAB
# of Institutions
253Shares Held
65.6MCall Options Held
32.5KPut Options Held
55K-
Alliancebernstein L.P. New York, NY10.7MShares$306 Million0.08% of portfolio
-
Orbis Allan Gray LTD Hamilton, D07.92MShares$227 Million1.07% of portfolio
-
Black Rock Inc. New York, NY5.08MShares$146 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.57MShares$102 Million0.01% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA3.45MShares$99.2 Million0.05% of portfolio
About GENMAB A/S
- Ticker GMAB
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 658,292,992
- Market Cap $18.9B
- Description
- Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...